Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05380505 · ClinicalTrials.gov registry record · NA
Influence of Social Media Ads on Food Choice
A NA study, sponsored by NYU Langone Health.
- Completed
- Registry status
- NA
- Development phase
- 1,252
- Enrollment target
NCT05380505: Completed NA study, sponsored by NYU Langone Health.
NCT05380505 is a NA study that has completed, run by NYU Langone Health. The registered enrollment target is 1,252 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (11% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05380505, a NA study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,252 participants
- Enrollment target
Study Summary
This is a randomized trial to examine the influence of race-congruent food marketing on social media among Black and White adolescents.
Interventions
- BEHAVIORAL Racially Congruent Ads
- BEHAVIORAL Racially Incongruent Ads
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,252 participants |
| Start Date | 2022-03-16 |
| Est. Completion | 2023-03-04 |
| Phase | NA |
What the finished NCT05380505 record still lists
NCT05380505 is an interventional study that assigns participants to a tested intervention. Its 1,252 participants enrollment target places it among the larger protocols in the corpus, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (11% lower).
The record links to 0 conditions, and to 2 interventions - of which Racially Congruent Ads is the first listed.
NCT05380505 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05380505 about?
NCT05380505 is a clinical study titled "Influence of Social Media Ads on Food Choice". This is a randomized trial to examine the influence of race-congruent food marketing on social media among Black and White adolescents.
What is the current status of trial NCT05380505?
This trial is currently completed. It is a NA study. The enrollment target is 1,252 participants. The study started on 2022-03-16. Estimated completion is 2023-03-04.
What interventions are being tested in trial NCT05380505?
The interventions under investigation include: Racially Congruent Ads (BEHAVIORAL), Racially Incongruent Ads (BEHAVIORAL).
Who is sponsoring clinical trial NCT05380505?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05380505's enrollment target sits among peer trials
1,252 80th of 2000 higher than 1,921 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02743858 · 1,250 participants
Lymphedema Surveillance Study
- NCT04670874 · 1,250 participants
Quality of Life in Cutaneous Lymphoma Patients Using the Skindex29
- NCT04807868 · 1,250 participants
AdventHealth Research Institute Non-Alcoholic Fatty Liver Disease Biobank and Registry (AVAIL)
- NCT05995821 · 1,250 participants
Immunobiology Blood and Tissue Collection of Upper Aerodigestive Malignancies
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI